However, maximum benefitsparticularly related to weight lossoften appear after several months of consistent use
This hormone is a key regulator of appetite and cravings
Tirzepatide, a dual glucagon-like peptide-1 (GIP) and GLP-1RAs, administered once weekly at a 15 mg dose, resulted in an average weight loss of 20.9% over 72 weeks (Jastreboff et al., 2022), driven by its synergistic effects on appetite regulation, energy intake reduction, and fat mass decrease (Heise et al., 2023)
GIP receptor (present in retatrutide and tirzepatide, absent in survodutide): Glucose-dependent insulinotropic polypeptide (GIP) enhances insulin secretion in a glucose-dependent manner, promotes nutrient uptake and lipid metabolism in adipose tissue, and may improve adipose tissue remodeling
Some users find that the neurochemical effects are most pronounced in the 24 to 72 hours following injection, creating a predictable pattern of side effect intensity throughout the week